Use of substituted 1-amino-5-phenylpentane-3-ol and/or 1-amino-6-phenylhexane-3-ol compounds as medicaments

A method of modifying the physiological or pathophysiological processes of a patient comprising administering to the patient a physiologically modifying amount of a compound having NMDA antagonistic effect and selected from the group consisting of substituted 1-amino-5-phenylpentane-3-ol and substituted 1-amino-6-phenylhexane-3-ol compound with general formula I,

• where
• n=1 or 2,
• group A represents an optionally substituted aryl or heteroaryl group,
• groups R1 and R2, the same or different, stand for a C1-6 alkyl group or groups R1 and R2 together form a (CH2)2-6 chain, which may also be phenyl substituted or may be attached to a phenyl ring to form a bicyclic system in which the cyclic aliphatic moiety and the phenyl ring share two carbon atoms and groups R3 to R8 and A have the meaning according to general formula I,
• groups R3 and R4, the same or different, stand for a C1-6 alkyl group, an optionally substituted aryl group or an optionally substituted aryl group which is bound via a C1-3 alkylene group, or groups R3 and R4 together represent (CH2)3-6 or CH2CH2OCH2CH2,
• groups R5, R6 and R7, the same or different, represent H, F, Cl, Br, I, CF3, OR8, SO2CH3, SO2CF3, phenyl, CN, NO2 or a C1-6 alkyl group,
• group R8 stands for H, a C1-6 alkyl group, an optionally substituted aryl group, an optionally substituted heteroaryl group or for, an optionally substituted aryl or heteroaryl group which is bound via a C1-3 alkylene group,
• diastereomers of such compounds, enantiomers of such compounds, physiologically tolerable salts of such compounds, and mixtures thereof.